NGO says EU FTA exclusivity demands on India may damage world generics supply
This article was originally published in SRA
Executive Summary
The EU should eliminate "demands that India adopt exclusive rights on drug test data, or lower its standards for granting patents on medical inventions", says the director of the Washington, DC-based non-governmental organisation, Knowledge Ecology International, in a 22 March BMJ article1.
You may also be interested in...
Biocon Biologics CEO Makes Surprise Exit
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
Biocon Biologics CEO Makes Surprise Exit
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
Prices Plunge As Xarelto Generics Arrive In India
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: